- Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales
- Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing
- 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year
- Chief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership
Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results [1] and provided a first outlook for 2026.
To access the full release, please click on the PDF below.
[1] The financial figures presented in this release are preliminary and unaudited. The final audited financial results, which remain subject to approval by the Board of Directors, are expected to be published in March.